Cargando…

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review

BACKGROUND AND OBJECTIVE: The genetic nature of cancer provides the rationale to support the need for molecular diagnosis and patient selection for individualised antineoplastic treatments that are the best in both tolerability and efficacy for each cancer patient, including non-small cell lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spagnuolo, Alessia, Maione, Paolo, Gridelli, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271439/ https://www.ncbi.nlm.nih.gov/pubmed/35832439 http://dx.doi.org/10.21037/tlcr-21-948

Ejemplares similares

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
por: Spagnuolo, Alessia, et al.
Publicado: (2023)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
por: Gridelli, C, et al.
Publicado: (2003)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
por: Schettino, Clorinda, et al.
Publicado: (2008)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues
por: Casaluce, Francesca, et al.
Publicado: (2021)

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
por: Gargiulo, Piera, et al.
Publicado: (2021)

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them
por: Rocco, Danilo, et al.
Publicado: (2022)

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
por: Wang, Judy, et al.
Publicado: (2022)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
por: Watanabe, Naohiro, et al.
Publicado: (2022)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
por: Passarelli, Anna, et al.
Publicado: (2020)

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
por: Rocco, Danilo, et al.
Publicado: (2023)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up
por: Setoguchi, Kensuke, et al.
Publicado: (2021)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
por: O’Sullivan, Éabha, et al.
Publicado: (2023)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation
por: Wu, Wei, et al.
Publicado: (2022)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jcpa1ippunh8p049eaitdl0jil